PROVEN INHALED PAH EFFICACY
The only inhaled PAH therapy to demonstrate significant clinical improvement through a combined endpoint at week 121
Learn More:
 
PRECISION DOSING
Learn about how the I-neb AAD system delivers precise dosing of Ventavis2,3
Learn More:
Faster Treatments For Convenience*
Higher 20 mcg/mL concentration shortens treatment times for patients who have repeatedly experienced extended treatment times on the 5 mcg dose*†
Learn More:

*The 20-mcg/mL concentration is intended for patients who are maintained at the 5-mcg dose and who have repeatedly experienced extended treatment times which could result in incomplete dosing. Ventavis 10-mcg/mL ampules are still available. Ventavis should be taken 6 to 9 times daily, at least 2 hours apart.1

†Based on an in vitro study with a manually generated 28.3-L/min, 15-sec inhalation cycle breathing pattern.

Respironics and I-neb Adaptive Aerosol Delivery (AAD) are trademarks of or belonging to Koninklijke Philips Electronics N.V.

For more information about Ventavis, please call 1-866-ACTELION (1-866-228-3546).

Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Important Safety Information

Please see full Prescribing Information.

Indication and Important Safety Information

 OPEN CLOSE

Indication:

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

Important Safety Information

  • Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHg.
  • Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.
  • Ventavis inhalation may cause bronchospasm and patients with a history of hyperreactive airway disease may be more sensitive.
  • Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis.
  • In clinical studies, the most common adverse events occurring more often (≥6%) in Ventavis-treated patients than in patients taking placebo included vasodilation (flushing) (27% vs 9%), cough (39% vs 26%), headache (30% vs 20%), trismus (12% vs 3%), and insomnia (8% vs 2%).
  • Ventavis has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.
  • Ventavis also has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information.